TY - JOUR
T1 - Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS
AU - Gedik, Kader Cetin
AU - Ortega-Villa, Ana M.
AU - Materne, Grace
AU - Rastegar, Andre
AU - Montealegre Sanchez, Gina A.
AU - Reinhardt, Adam
AU - Brogan, Paul A.
AU - Berkun, Yackov
AU - Murias, Sara
AU - Robles, Maria
AU - Schalm, Susanne
AU - de Jesus, Adriana A.
AU - Goldbach-Mansky, Raphaela
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2024.
PY - 2024/8/27
Y1 - 2024/8/27
N2 - Objectives Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/ proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to the janus kinase inhibitor 1/2 inhibition with baricitinib at exposures higher than in rheumatoid arthritis. Baricitinib dose reductions to minimise exposure triggered disease flares which we used to develop’flare criteria’. Methods Of 10 patients with CANDLE/PRAAS treated with baricitinib in an open-label expanded-access programme, baricitinib doses were reduced 14 times in 9 patients between April 2014 and December 2019. Retrospective data analysis of daily diary scores and laboratory markers collected before and after the dose reductions were used to develop’clinical’ and’subclinical’ flare criteria. Disease flare rates were compared among patients with <25% and >25% dose reductions and during study visits when patients received recommended’optimized’ baricitinib doses (high-dose visits) versus lower than recommended baricitinib doses (low-dose visits) using two-sided χ2 tests. Results In the 9/10 patients with CANDLE with dose reduction, 7/14 (50%) times the dose was reduced resulted in a disease flare. All four dose reductions of >25% triggered a disease flare (p <0.05). Assessment of clinical and laboratory changes during disease flares allowed the development of disease flare criteria that were assessed during visits when patients received high or low doses of baricitinib. Disease flare criteria were reached during 43.14% of low-dose visits compared with 12.75% of high-dose visits (p <0.0001). Addition of an interferon score as an additional flare criterion increased the sensitivity to detect disease flares. Conclusion We observed disease flares and rebound inflammation with baricitinib dose reductions and proposed flare criteria that can assist in monitoring disease activity and in designing clinical studies in CANDLE/PRAAS.
AB - Objectives Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/ proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to the janus kinase inhibitor 1/2 inhibition with baricitinib at exposures higher than in rheumatoid arthritis. Baricitinib dose reductions to minimise exposure triggered disease flares which we used to develop’flare criteria’. Methods Of 10 patients with CANDLE/PRAAS treated with baricitinib in an open-label expanded-access programme, baricitinib doses were reduced 14 times in 9 patients between April 2014 and December 2019. Retrospective data analysis of daily diary scores and laboratory markers collected before and after the dose reductions were used to develop’clinical’ and’subclinical’ flare criteria. Disease flare rates were compared among patients with <25% and >25% dose reductions and during study visits when patients received recommended’optimized’ baricitinib doses (high-dose visits) versus lower than recommended baricitinib doses (low-dose visits) using two-sided χ2 tests. Results In the 9/10 patients with CANDLE with dose reduction, 7/14 (50%) times the dose was reduced resulted in a disease flare. All four dose reductions of >25% triggered a disease flare (p <0.05). Assessment of clinical and laboratory changes during disease flares allowed the development of disease flare criteria that were assessed during visits when patients received high or low doses of baricitinib. Disease flare criteria were reached during 43.14% of low-dose visits compared with 12.75% of high-dose visits (p <0.0001). Addition of an interferon score as an additional flare criterion increased the sensitivity to detect disease flares. Conclusion We observed disease flares and rebound inflammation with baricitinib dose reductions and proposed flare criteria that can assist in monitoring disease activity and in designing clinical studies in CANDLE/PRAAS.
UR - http://www.scopus.com/inward/record.url?scp=85191823224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85191823224&partnerID=8YFLogxK
U2 - 10.1136/ard-2023-225463
DO - 10.1136/ard-2023-225463
M3 - Article
C2 - 38653530
AN - SCOPUS:85191823224
SN - 0003-4967
VL - 83
SP - 1181
EP - 1188
JO - Annals of the rheumatic diseases
JF - Annals of the rheumatic diseases
IS - 9
ER -